Search results
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks via Yahoo Finance· 2 days agoNovavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 6 days agoThis is appealing to people who are uneasy with the newer mRNA technology. But the competitor...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 6 days agoYounger children, adults 65 and older and immunocompromised people may need multiple doses, the...
FDA asks COVID vaccine makers to target KP.2 strain, if feasible, for next shot
Reuters via Yahoo News· 5 days agoThe Food and Drug Administration's change in recommendation, in an update dated Thursday, comes even...
FDA advises Covid vaccine makers to target KP.2 for fall shots
NBC News via Yahoo News· 6 days agoThe FDA advised drugmakers to update Covid vaccines to target the KP.2 strain, a descendant of the...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 5 days agoOn June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held...
Jim Cramer Says He's 'Going To Have To Wait' On SoFi, But Recommends This 'Great Little Industrial...
Benzinga· 2 days agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer said he still can't recommend Twilio TWLO. On June...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News via Yahoo News· 4 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
FDA recommends COVID jab manufacturers update formulas to combat new strain
BizPac Review· 4 days agoA new strain of COVID has prompted recommendations for vaccine companies to update their formulas in anticipation of cases in the fall. The U.S. Food and Drug Administration (FDA< ...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 5 days agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....